Evaluation of new chalcone derivatives as polyphenol oxidase inhibitors

Sönmez, Fatih; Sevmezler, Sedat; Atahan, Alparslan; Ceylan, Mustafa; Demir, Dudu; Gençer, Nahit; Arslan, Oktay; Küçükislamoğlu, Mustafa

doi:10.1016/j.bmcl.2011.09.130

Cited by 56 publications

(34 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These studies have reported that a hydrogen bond has been formed between amid moieties of the inhibitors and anionic sites of the enzyme [25,26]. The urea group was chosen on the basis of its potency of H-bonding, probability of complexation and wide biological activity [27][28][29][30]. We report here a new hybrid molecule (1) based on frameworks of the coumarin modified by the addition of thiazole ring (Fig.…”

Section: Introductionmentioning

confidence: 99%

Synthesis, antioxidant and anticholinesterase activities of novel coumarylthiazole derivatives

Kurt

Gazioğlu

Sönmez

et al. 2015

Bioorganic Chemistry

Self Cite

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 99%

Synthesis, antioxidant and anticholinesterase activities of novel coumarylthiazole derivatives

Kurt

Gazioğlu

Sönmez

et al. 2015

Bioorganic Chemistry

Self Cite

View full text Add to dashboard Cite

“…Both reactions are catalysed by tyrosinase and the oxidations of L-tyrosine to L-DOPA and to melanin pigment follow each other consecutively (Goldfeder et al 2013). The o-quinone form of L-DOPA, via a series of steps, self-polymerises (non-enzymatically) to form melanin (Faccio 2012;Sonmez 2011). The oxidation pathway of HGA into ochronotic pigment is presumed to be similar to the L-tyrosine-L-DOPA-melanin pathway (Roberts et al 2015).…”

Section: Introductionmentioning

confidence: 99%

Analysis of Melanin-like Pigment Synthesized from Homogentisic Acid, with or without Tyrosine, and Its Implications in Alkaptonuria

Taylor

Vercruysse

2016

JIMD Reports

View full text Add to dashboard Cite

Alkaptonuria is an iconic disease used by Archibald Garrod to demonstrate the theory of "inborn errors of metabolism". AKU knowledge has advanced in recent years: development of an in vitro model, discovery of murine models and advances in understanding bone and cartilage phenotypes and arthropathy in AKU. These discoveries have aided in a new clinical trial into nitisinone. However, there are still knowledge gaps surrounding the pigment in AKU and the pigmentation process. We demonstrate an advance in the understanding in the kinetics and chemistry of the polymerisation of homogentisic acid (HGA) into its pigment using size-exclusion chromatography and IR spectroscopy. We compared the properties of HGA-based pigments that were freshly prepared to those stored in solution for 2 years. Our results demonstrate the importance of pH in the polymerisation process and that colour change seen in solution (analogous to AKU patient urine) is not initially due to presence of ochronotic pigment but the quinone intermediary. In addition, we observed that pigment formation from HGA can occur in the presence of tyrosine, without the inclusion of this tyrosine into the pigment. These observations have positive implications for patients with alkaptonuria; an increased understanding of the pigment polymer chemistry, the presence of an intermediary and their kinetics present more therapeutic opportunities for treating the condition, including preventing the pigment from forming, binding or reversing established pigmentation. AKU patients treated with nitisinone show elevated tyrosine levels causing side effects such as corneal opacities; our data demonstrates that elevated tyrosine levels should not contribute or add to the ochronotic pigment burden in these patients.

show abstract

“…That is why enzyme inhibition studies are an important issue for drug design and biochemical applications (Alim & Beydemir, 2012;Demir et al, 2012a, b;Sayin et al, 2012;Sonmez et al, 2011). This study is the first report on the inhibition of cytosolic carbonic anhydrases by various antipsychotic drugs.…”

Section: Resultsmentioning

confidence: 80%

Antipsychotic agents screened as human carbonic anhydrase I and II inhibitors

Erzengin

Bilen

Ergün

et al. 2013

Archives of Physiology and Biochemistry

Self Cite

View full text Add to dashboard Cite

The antipsychotic drugs currently used to treat schizophrenia can be divided into two distinct classes, typical and atypical antipsychotics. Many drug molecules are enzyme inhibitors that bind reversibly or irreversibly to their target through intermolecular interactions. That's why enzyme inhibition studies are an important issue for drug design and biochemical applications. In this study, in vitro inhibition effect of some antipsychotic drugs on the purified carbonic anhydrase (CA) I and II isoenzymes were investigated by using CO2 as a substrate. CA I and II were purified from human erythrocytes by a simple one step procedure using Sepharose 4B-L-tyrosine-sulfonamide affinity column. The results showed that all the drugs inhibited the cytosolic carbonic anhydrases enzyme activity in a concentration-dependent fashion. Among the studied drugs, aripiprazole and pramipexole were found to be the most active one for hCA I (IC50: 3.64 and 5.37 μM) and hCA II (IC50: 4.16 and 4.81 μM) activity, respectively.

show abstract

Evaluation of new chalcone derivatives as polyphenol oxidase inhibitors

Cited by 56 publications

References 41 publications

Synthesis, antioxidant and anticholinesterase activities of novel coumarylthiazole derivatives

Synthesis, antioxidant and anticholinesterase activities of novel coumarylthiazole derivatives

Analysis of Melanin-like Pigment Synthesized from Homogentisic Acid, with or without Tyrosine, and Its Implications in Alkaptonuria

Antipsychotic agents screened as human carbonic anhydrase I and II inhibitors

Contact Info

Product

Resources

About